Pregnancy Recommendations Solely Based on Preclinical Evidence Should Be Integrated with Real-World Evidence: A Disproportionality Analysis of Certolizumab and Other TNF-Alpha Inhibitors Used in Pregnant Patients with Psoriasis

• Päätekijät: Mario Gaio (Tekijä), Maria Giovanna Vastarella (Tekijä), Maria Giuseppa Sullo (Tekijä), Cristina Scavone (Tekijä), Consiglia Riccardi (Tekijä), Maria Rosaria Campitiello (Tekijä), Liberata Sportiello (Tekijä), Concetta Rafaniello (Tekijä)
• Aineistotyyppi: Kirja
• Julkaistu: MDPI AG, 2024-07-01T00:00:00Z.
• Aiheet: article
• Linkit: Connect to this object online.

Treatment for pregnant women with psoriasis is limited by the lack of information typically related to clinical trials. While anti-tumor necrosis factor (TNF) drugs offer therapeutic benefits, their safety during pregnancy is a concern. Notably, certolizumab is comparatively safer than adalimumab, e...